| Registry | NCT03386201, acronym FLoCaMB |
|---|---|
| Status | Unknown |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, other |
| Enrollment | 40 (Estimated) |
| Sponsor | University of Oxford (Other); collaborators: Oxford University Hospitals NHS Trust |
| Conditions | Bile Duct Injury |
| Interventions | Intravenous Methylene blue (Drug) |
| Dates | start 2018-01-01 (estimated), primary completion 2018-06-01 (estimated), completion 2018-06-01 (estimated), first posted 2017-12-29, last updated 2017-12-29 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Bile Duct Injury All trials of Intravenous Methylene blue
Open label prospective, non-randomised proof of principle study assessing the use of methylene blue fluorescence cholangiography.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Intravenous methylene blue | Experimental | Drug: Intravenous Methylene blue |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years or above. * Undergoing laparoscopic cholecystectomy Exclusion Criteria: * Patient who is unable or unwilling to give informed consent * Known allergy to methylene blue * Risk of serotonin syndrome (taking SSRI / G6PD deficiency / previous serotonin syndrome) * Significant renal failure * Pregnant / planning pregnancy or breastfeeding
| Facility | City | Country | Status |
|---|---|---|---|
| Oxford University Hospitals NHS Foundation Trust | Oxford | United Kingdom | Recruiting |